Recent Updates
Recently added Catalysts

Darigabat

Phase 1

Healthy | Small molecule | Other |AbbVie Inc.|Last Updated: Jan 20, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment12
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05123079Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy ParticipantsPHASE1 COMPLETED 12Nov 1, 2021Dec 1, 2021Jan 20, 2022 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
DarigabatDRUGTablets
Unlock Study Design Details